ABG
ACET icon

Ally Bridge Group’s Adicet Bio ACET Stock Holding History

Ally Bridge Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,275
Closed -$3.48M – 31
2022
Q3 		$3.48M Buy
+15,275
New +$3.88M 2.29% 19
2021
Q4 		– Sell
-26,563
Closed -$3.33M – 31
2021
Q3 		$3.33M Hold
26,563
– – 0.98% 29
2021
Q2 		$4.37M Hold
26,563
– – 1.09% 26
2021
Q1 		$5.56M Buy
+26,563
New +$6.1M 1.07% 27

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ally Bridge Group's ACET Position: Q4 2022 in Review

Ally Bridge Group sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 15,275 shares — an estimated $3.48M sold.

Ally Bridge Group first reported a position in ACET in Q1 2021 and held it in 4 quarters. The position peaked at $5.56M in Q1 2021. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • Ally Bridge Group reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • Ally Bridge Group sold 15,275 Adicet Bio shares in Q4 2022, an estimated $3.48M.
  • Ally Bridge Group first reported a position in Adicet Bio in Q1 2021 and held it in 4 quarters.
  • Ally Bridge Group's Adicet Bio position peaked at $5.56M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.